top of page
Biochemical Recurrence: Insights from AUA/ASTRO/SUO Guidelines with Dr. Todd Morgan, Dr. Aditya Bagrodia on the BackTable Urology Podcast
00:00 / 01:04

Save your progress. Continue watching on the BackTable app.

BackTable Urology

Episode # 206  •  17 Dec 2024

Biochemical Recurrence: Insights from AUA/ASTRO/SUO Guidelines

Have you checked out the AUA/ASTRO/SUO’s recently released guidelines for salvage therapy in prostate cancer biochemical recurrence? In this episode of the BackTable Urology Podcast, guest Dr. Todd Morgan from the University of Michigan and host Dr. Aditya Bagrodia continue with part two of our series on prostate cancer biochemical recurrence management.

This podcast is supported by

Veracyte

Timestamps

00:00 - Introduction
03:41 - Consensus Biochemical Recurrence Guidelines
08:56 - Evolution of Post-Prostatectomy Biochemical Recurrence Management
13:24 - Patient Counseling and Risk of Recurrence
17:42 - PSMA PET Scans
20:44 - Postoperative PSA Monitoring
28:35 - The Role of Radiation
31:56 - Hormone Therapy
39:00 - Salvage Lymphadenectomy
46:30 - Future Directions and Concluding Thoughts

Resources

You may also like

See more of the content that's relevant to your practice.

More about this episode

The doctors focus on the difficulty in declaring a patient 'cured' and the implications of biochemical recurrence after treatment. Dr. Morgan highlights the importance of PSA in the postoperative setting and explores the role of the Decipher Prostate Genomic Classifier in personalizing treatment. He talks through the latest AUA/ASTRO/SUO consensus on biochemical recurrence guidelines, including the significance of early salvage therapy and the integration of advanced imaging techniques like PSMA PET scans. Further, Dr. Morgan emphasizes the role for multidisciplinary evaluation, patient counseling, and future directions of research to refine treatment options.

This discussion underscores the transition from adjuvant to early salvage radiation as a standard practice and considers emerging biomarker strategies to inform treatment decisions.

The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.

bottom of page